Mechanism of Action
MC1R Agonism and Melanogenesis
afamelanotide/" class="wiki-internal-link">Afamelanotide binds with high affinity to MC1R on melanocytes, activating cAMP-PKA signaling that drives upregulation of microphthalmia-associated transcription factor (MITF). MITF in turn transcriptionally activates the key melanogenic enzymes: tyrosinase, TYRP-1, and DCT. The result is accelerated eumelanin (brown-black) synthesis and melanosome transfer to keratinocytes. Eumelanin is a more effective UV absorber and antioxidant than phaeomelanin, providing genuine photoprotective benefit independent of tanning appearance. This is the mechanism underlying the EPP indication: increased epidermal melanin reduces porphyrin-mediated phototoxicity.
DNA Protection and Anti-inflammatory Effects
Beyond cosmetic tanning, MC1R activation via afamelanotide reduces UV-induced DNA damage (cyclobutane pyrimidine dimers, 6-4 photoproducts) in keratinocytes through both melanin-absorptive mechanisms and direct upregulation of nucleotide excision repair pathways. Anti-inflammatory effects are mediated via reduced NF-kB activation and decreased UV-induced IL-6 and TNF-alpha secretion. These properties have generated research interest in photodermatology beyond EPP, including in polymorphous light eruption, solar urticaria, and potentially skin cancer prevention.
Differences from Melanotan II
Melanotan II (MT-II) is a cyclic heptapeptide with MC3R and MC4R activity in addition to MC1R, the MC4R activity drives its central aphrodisiac effects and contributes to appetite suppression. Afamelanotide (MT-I) is linear and 13 amino acids, with more selective MC1R activity and negligible CNS effects at typical doses. This profile makes afamelanotide more suitable for photoprotection and dermatological applications, while MT-II's broader receptor activity makes it the target for sexual dysfunction research. The two peptides are frequently confused but represent meaningfully different pharmacology.
Research Summary
EPP Photoprotection (FDA Approval Basis)
RegulatoryThe FDA approval of Scenesse (16 mg subcutaneous implant, released over ~60 days) was based on two Phase III RCTs in EPP patients. The primary endpoint, hours of pain-free sun exposure - increased by approximately 70% versus placebo. Secondary endpoints including quality of life measures and reduction in phototoxic episodes were also significantly improved. The implant formulation was developed to maintain stable plasma levels and avoid peak/trough cycling from injectable dosing. Approval was granted in October 2019 (US) following earlier EU approval in 2014.
Vitiligo and Photodermatology
Moderate EvidencePhase I/II data supports afamelanotide combined with narrowband UVB for vitiligo repigmentation. The peptide increases the melanocyte response to UV treatment, leading to faster and more complete repigmentation in preliminary studies. A 2015 RCT (Grimes et al) showed significantly greater repigmentation area in the afamelanotide + NB-UVB arm versus NB-UVB alone.
Cosmetic Tanning Research
Moderate EvidenceEarlier Phase I/II studies at the University of Arizona by Dorr et al in the 1990s established human tanning dose-response for SC afamelanotide. Daily or alternate-day injections of 0.5-1 mg produced consistent melanin densitometry increases over 2-4 weeks. The tanning response persisted for 1-3 weeks after cessation. These studies formed the pharmacological foundation for the subsequent EPP program.
Calculate your Melanotan I dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Photoprotection / tanning | 0.5-1 mg | Daily x 2 weeks, then EOD | Subcutaneous |
| Vitiligo (adjunct NB-UVB) | 1 mg | Per dermatology protocol | Subcutaneous with phototherapy |
| EPP, pharmaceutical (Scenesse) | 16 mg implant | Every 60 days | Physician-placed implant only |
Afamelanotide does not require sunlight exposure to stimulate melanin synthesis (unlike tanning beds). However, the melanin density increase provides better photoprotection once achieved. Nausea is the most common side effect, co-administration of an antiemetic before injection may help during the loading phase.
Interactions
Safety Profile
Afamelanotide has the most robust human safety dataset of any melanocortin research peptide, supported by multiple Phase III RCTs and post-marketing pharmacovigilance from the EU approval (since 2014). Common adverse effects: nausea (dose-dependent, attenuated by splitting doses), fatigue, headache, flushing, and hyperpigmentation of existing moles (requires monitoring). Nevi monitoring is recommended for prolonged use; no evidence of melanoma induction has emerged in clinical trials or post-marketing surveillance. It does not significantly bind MC4R at standard doses, avoiding the priapism and appetite suppression seen with MT-II. No cardiovascular safety signals have emerged. Contraindicated in history of melanoma or high-risk dysplastic nevi.
References
- [1]Langendonk JG et al. "Afamelanotide for Erythropoietic Protoporphyria." N Engl J Med. 2015;373(1):48-59.
- [2]Grimes PE et al. "Afamelanotide and Narrowband UV-B for Vitiligo." JAMA Dermatol. 2013;149(1):68-73.
- [3]Dorr RT et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sci. 1996;58(20):1777-1784.
- [4]FDA. "SCENESSE (afamelanotide) Prescribing Information." Clinuvel Pharmaceuticals, 2019.